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Abstract:
Background: The literature suggests that the prevalence of atrial fibrillation (AF) may be lower in Asian countries than in Western 
countries. Nevertheless, AF remains a significant public health problem in the region. The burden of AF, the experiences of previous 
trials and the lack of data on AF and its management in Asia Pacific highlight the need for a comprehensive prospective study of AF 
management.
Methods: The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation Asia Pacific (RecordAF-AP) is a 
prospective, observational survey of the management of recently diagnosed AF patients with 1-year follow-up in 8 countries across 
Asia Pacific. Eligible patients presenting with AF, treated or not, will be included in the registry and data will be recorded prospectively 
during follow-up visits at 6 and 12 months.
Results: RecordAF-AP will recruit more than 3000 patients. Study recruitment commenced in April 2009 and the final results   anticipated 
at the end of 2011.
Conclusions: RecordAF-AP will assess the real-life management of AF patients in Asia Pacific, including a comparison of clinical 
outcomes in rhythm versus rate control strategies, providing much needed insight into the costs, treatment choices and clinical outcomes 
of AF patients in this region.
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Introduction
Atrial fibrillation (AF) is the most common cardiac 
arrhythmia; its prevalence increases with age such 
that 70% of cases occur in patients aged 65 years and 
older.1 AF is a progressive disease that often worsens 
over time and is both a contributory factor to and an 
indicator of progressive cardiovascular disease. For 
example, AF increases the risk of stroke by 5-fold2 
and the risk of heart failure by 3-fold.3 AF causes con-
siderable morbidity and mortality, negatively impacts 
quality of life and well-being and imposes signifi-
cant burden on health care systems.4 Aging popula-
tions,  increasing  prevalence  of  comorbidities  and 
more effective treatment of cardiovascular diseases 
are all contributing to the increasing incidence of AF 
and its associated health care burden.5 As a result, the 
  societal impact of AF is expected to double over the 
next three decades.6
Literature regarding the clinical epidemiology of 
AF in non-white populations is limited.7 Data from 
the US indicates that AF is more common in white 
versus black patients who are aged 60 years or   older.8 
Available  data  suggests  that  the  prevalence  of AF 
may be lower in Asian countries (Singapore,9 Korea,10 
Malaysia7  and  mainland  China11)  than  in  Western 
countries, although it should be borne in mind that 
differences in diagnosis and population characteris-
tics across these studies could have had some impact 
on the results obtained. Nevertheless, AF remains a 
significant public health problem.11
Management of AF involves two key objectives—
prevention of thromboembolism and symptom man-
agement. Initial symptom management, according to 
current guidelines, involves either the restoration of 
and maintenance of sinus rhythm (rhythm control) 
or the control of ventricular response (rate control).12 
Non-pharmacological and pharmacological therapies 
are used in both strategies. No significant differences 
between rate and rhythm control with respect to mor-
tality,  major  bleeding  and  thromboembolic  events 
have been demonstrated.13–19
Several  antiarrhythmic  drugs  are  available  and 
have been demonstrated to be effective in reducing 
the recurrence of AF after conversion to sinus rhythm 
but are limited by adverse events.20 Given these limi-
tations, chronic management of AF remains difficult 
for both patient and physician. Advances in avail-
able  medical  treatments,  in  particular  dronedarone 
and  dabigatran,  offer  the  possibility  of  changes  in 
  treatment  paradigms  and  a  greater  emphasis  on 
reducing   hospitalizations and improvement in long-
term outcomes.5 Despite these therapeutic advances, 
there remains a need to investigate further the real-
life management of AF.
Prospective  data  from  the  Euro  Heart  Survey 
shows divergence between guidelines and day to day 
clinical practice,21 with under-treatment being asso-
ciated with a significantly higher chance of throm-
boembolism.22  The  Registry  on  Cardiac  rhythm 
disorders assessing the control of Atrial Fibrillation 
(RecordAF)  is  the  first  worldwide,  1-year  obser-
vational, longitudinal study of the management of 
paroxysmal/persistent atrial fibrillation in recently 
diagnosed patients (n = 5604). The results of this 
study will provide a global perspective on current 
treatment strategies for AF. The design and baseline 
data from 532 sites in 21 countries across Europe, 
America and Asia have recently been published.23 
Patient data have been contributed from Australia, 
South  Korea,  Philippines  and  Thailand,  but  they 
account for only 12.3% (n = 715) of the total popu-
lation studied. The burden of AF, the experiences of 
previous trials and the lack of data on AF and its 
management in Asia Pacific highlight the need for 
a comprehensive prospective study of AF manage-
ment in day to day practice. In this paper we discuss 
the methodology of an extension of the RecordAF 
study, RecordAF-AP, the intent of which is to pro-
duce a large-scale prospective Asia Pacific database 
on the management of AF.
patients and Methods
RecordAF-AP is a prospective, observational survey 
of the management of recently diagnosed AF patients 
with a 1-year follow-up. The primary objective of the 
study is to prospectively assess AF control over 1 year 
in patients attending clinical or specialized practices 
in order to compare clinical outcomes in rhythm ver-
sus rate control strategies. The study will also describe 
the key demographics and treatment modalities of AF 
patients across the Asia Pacific region, determine any 
associations between the pharmacological treatment 
of AF  and AF  control,  determine  any  associations 
between control of AF and clinical outcomes and col-
lect information on suspected adverse events to the 
treatment prescribed for AF.RecordAF (Asia Pacific)
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The  study  will  recruit  more  than  3000  patients 
from  8  countries  across  Asia  Pacific  (Australia 
[20 sites], China [20 sites], Hong Kong [3 sites], Korea 
[20 sites], Malaysia [5 sites], Philippines [4 sites], 
Taiwan [15 sites] and Thailand [30 sites]). Partici-
pating  investigators  have  been  randomly  selected 
and are representative of cardiologists who manage 
AF patients based upon the expertise and healthcare 
structure of each participating country. The study will 
be conducted in accordance with the Declaration of 
Helsinki (as amended in 2004),24 guidelines for Good 
Epidemiological Practice25 and local regulations. Eth-
ics approval has been sought and provided locally by 
each participating country.
Patient  inclusion  and  exclusion  criteria  are  the 
same  as  have  been  previously  described  for  the 
RecordAF study23 and are summarized in Table 1. 
Eligible patients are to be included irrespective of the 
reason for their visit to the participating cardiologist. 
Data will be collected at baseline (visit 1) and during 
routine follow-up visits at 6 ± 2 months (visit 2) and 
Table 1. Patient selection criteria.
Inclusion 
criteria
• Male or female aged $18 years
• Presenting with one of the following:
  •   history of AF diagnosed #1 year by  
standard eCg or by eCg-holter 
monitoring (patient may be either treated 
or not treated at inclusion visit)
  •   New AF diagnosed standard eCg or by  
eCg-holter monitoring at inclusion visit
•   eligible for pharmacological treatment of  
AF (by rhythm or rate control agents)




• AF due to transient cause
• Post cardiac surgery AF (#3 months)
•   Life expectancy of ,1 year due to severe  
disease
•   Unable to understand or sign the written  
informed consent due to mental disability
• Unable to comply with follow-up visits
•   has a pacemaker or implantable  
cardioverter defribrilator*
•   Scheduled for pulmonary vein isolation,  
atrioventricular node/his bundle ablation or  
pacemaker implantation*
•   Participation in an AF clinical trial in the  
previous 3 months
• Pregnant or lactating
Note:  *These  patients  are  excluded  because  of  the  difficulties  in 
interpreting their rhythm/rate-control strategies.
12 ± 3 months (visit 3). During the 12 months from 
recruitment to end of study (visit 3), treatment includ-
ing the choice of medication, dosage and titration will 
be conducted at the doctor’s discretion.
The co-primary endpoints at 12 months’ follow 
up are the rate of therapeutic success and the inci-
dence  of  clinical  outcomes  in  rhythm  versus  rate 
control strategies. Therapeutic success, for a given 
patient at 12 ± 3 months follow-up, will be defined as 
either the presence of sinus rhythm (for patients with 
a  rhythm-control  strategy  at  baseline)  or  a  resting 
heart rate in the target range of #80 beats/min (for 
patients with a rate-control strategy at baseline) with 
no incidence of clinical outcomes and no cross-over 
between  rhythm  and  rate  control  strategies  during 
the follow-up period. Clinical outcomes are cardio-
vascular death, hospitalization for transient ischemic 
attack, myocardial infarction, hospitalization or pro-
longation of hospitalization for arrhythmic or proar-
rhythmic events, other cardiovascular events or major 
complications of ablative procedure. The secondary 
objectives, at 12 months follow-up, are assessment 
of  treatment  effectiveness  (proportion  of  patients 
in sinus rhythm or at rate control target, depending 
on the baseline strategy, with no symptoms of AF, 
still taking baseline medication, with no reports of 
treatment related adverse events, clinical outcomes, 
  cardioversion or ablation) and success rate   according 
to the   pharmacological treatment class, evaluation of 
the impact of cardiovascular risk factors on the occur-
rence of clinical events (cardiovascular death, myo-
cardial infarction, ischemic stroke, other arrhythmia, 
hospitalization for myocardial infarction, congestive 
heart failure episode, ischemic stroke or other arrhyth-
mia), collation of information on suspected adverse 
reactions to prescribed AF treatments. A summary of 
the primary and secondary objectives is provided in 
Table 2.
Statistical analysis will be based on all patients 
enrolled into the study; only patients with a baseline 
and a post-baseline assessment will be included in the 
analysis. Patients will be stratified to rate or rhythm 
control based on the therapeutic strategy selected at the 
inclusion visit. Descriptive data will be   summarized 
using mean and standard deviation and categorical 
data as number counts and percentages. The rate of 
patients in sinus rhythm or at rate control target will 
be provided with a 95% confidence interval (CI) and Amerena et al
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logistic regression models will be used for analysis 
of the cardiovascular event rate. Health related qual-
ity of life will be assessed at baseline and 12 months 
using  the  EQ-5D  questionnaire.26 The  EQ-5D  is  a 
self-  administered  descriptive  system  comprising 
five items (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) which provides 
a simple profile and an overall numeric estimate of 
health related quality of life.
The  Atrial  Fibrillation  Follow-up  Investigation 
of  Rhythm  Management  (AFFIRM)  study  was  an 
important  landmark  study  comparing  rhythm  and 
rate control strategies in terms of clinical outcomes. 
The  AFFIRM  sub-study  of  first  anti-arrhythmic 
drug,  performed  in  patients  randomized  to  rhythm 
control, compared different antiarrhythmic drugs by 
randomly assigning the first drug treatment to amio-
darone, sotalol or a class I drug.27 The primary end 
point was the proportion of patients alive, in sinus 
rhythm, with no additional cardioversions and still 
taking the assigned drug at one year. At one year, this 
primary endpoint was achieved in 62% of patients 
treated with amiodarone, compared with 23% taking 
class I agents (P , 0.001), 60% of patients treated 
with amiodarone, compared with 38% taking sotalol 
(P = 0.002) and 34% of patients treated with sotalol, 
compared with 23% taking class I agents (P = 0.488). 
Additionally, in the AFFIRM trial, after 5 years fol-
low-up, 35% of patients (with AF and a high risk for 
stroke or death) allocated to rate control strategy were 
in sinus rhythm (58% at 1 year) and 80% were at 
heart rate target. Among patients allocated to rhythm 
control strategy, 82% were in sinus rhythm at 1 year 
follow-up (decreasing to 63% at 5 years). Based on 
these data, the overall therapeutic success rate in the 
Record-AFAP  study  was  assumed  to  be  50%  at  1 
year.
Sample size calculation has determined that data 
from 384 evaluable patients in each geographic unit 
of interest are required to be able to estimate a thera-
peutic success rate of 50% at 1 year with a precision of 
5% for the 95% CI. Five regions of interest have been 
identified for this study: Australia, Korea, Taiwan, 
Thailand and other Asian countries (Malaysia, Hong 
Kong and Philippines). With a maximum expected 
lost to follow up rate of 25%, a total of 1,920 evalu-
able patients and 2,560 enrolled patients are needed.
Discussion
Available data from the global RecordAF study have 
already  provided  some  insight  into  the  manage-
ment of AF. Prior to the initiation of the RecordAF 
study,  one  cardiologist  from  each  of  the  583  sites 
in 6 regions completed a pre-study questionnaire in 
order that theoretical approaches to rhythm and rate 
control could be investigated.28 The results indicate 
some divergence from the American College of Car-
diology (ACC)/ American Heart Association (AHA)/
European Society of Cardiology (ESC) guidelines for 
the management of AF with regard to first-line drug 
selection in patients with AF and associated structural 
heart disease (SHD), AF and congestive heart failure 
(CHF) or lone AF. For AF patients with SHD, in all 
regions amiodarone was first choice amongst rhythm 
control agents and β blockers were the first choice 
amongst  rate  control  agents.  For AF  patients  with 
CHF, in all regions amiodarone was the first choice 
amongst rhythm control agents. There was, however, 
some variation with regard to first choice amongst 
rate control agents; β blockers were first choice in 
the US, Eastern Europe and North Western Europe 
whereas cardiac glycosides were first choice in Asia, 
South Western Europe and South/Central America. 
Finally, for patients with lone AF, β blockers were the 
first choice amongst rate control agents in all regions. 
With regard to choice of rhythm control agents, across 
all regions, propafenone (30.6%), flecainide (24.1%), 
and  amiodarone  (21.7%)  were  the  most  common 
choices. There was again some variance by specific 
Table 2. Record AF-AP registry objectives.
Primary •   Prospectively assess, over 1 year, disease   
control in AF patients in daily practice
•   Report clinical outcomes of rhythm- 
control and rate-control strategies
Secondary •   describe key demographics and treatment   
features of AF patients followed by 
cardiologists in various countries in  
Asia Pacific
•   determine the association between  
pharmacological treatments of AF and  
AF control
•   determine the association between control   
of AF and clinical outcomes
•   evaluate health status and resource  
utilisation
•   gather information on suspected adverse  
eventsRecordAF (Asia Pacific)
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region; in Asia amiodarone was the clear first choice 
whilst in Western Europe it was flecainide and in the 
US,  Eastern  Europe  and  South/Central America  it 
was propafenone.
The  recently  published  baseline  data  from 
RecordAF indicates that, in concert with AF treat-
ment guidelines, rhythm-control strategies are more 
likely to be used in younger patients, with recently 
diagnosed AF or paroxysmal AF than are rate-control 
strategies.23 Rhythm-control patients were more likely 
to be receiving β blockers and class III agents whilst 
β blockers and cardiac glycosides are more likely to 
be used in rate-control patients.
The RecordAF-AP study will enable assessment 
of the real-life success rate of rhythm and rate con-
trol  strategies  with  the  various  medical  treatments 
currently used in the Asia Pacific region. It will pro-
vide a specific and focused assessment of AF man-
agement in the Asia Pacific region as compared with 
the  global  perspective  provided  by  the  RecordAF 
study.23 The study will characterize current manage-
ment approaches for AF, including their costs and 
clinical outcomes, and provide insight into inherent 
differences in patient characteristics and population 
demographics across the region.
conclusion
Study recruitment for RecordAF-AP commenced in 
April 2009; baseline results are expected to be avail-
able by late 2010 and the final results by the end 
of 2011. The results are anticipated to yield further 
understanding of the rationale for selecting rhythm or 
rate control strategies, the rationale for drug selection, 
titration and switch and drop-out rates. An important 
aspect of the study will be to document the correla-
tion between hard clinical endpoints and success rates 
of therapies, as in the AFFIRM study,29 and assess the 
benefits of sinus rhythm maintenance. As such, this 
study  will  facilitate  rational  and  informed  choices 
regarding AF treatment strategies amongst healthcare 
professionals in the Asia Pacific region.
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